Epidemiological information on chronic myeloproliferative disorders (CMPDs), notably Philadelphia (Ph)/BCR-ABL-positive chronic myeloid leukemia (CML), is rare. 1 Reports from population-based registries [2] [3] [4] [5] show a high variability of crude and standardized incidences rates of 0.6-2.0 for CML and the other CMP entities. Few data are available on the proportion of patients recruited to clinical trials and on the representativity of study patients for the whole patient population. The median age of CML patients differs between cancer registries and clinical trials by 10-20 years. A Scottish study 6 indicates that only 52% of CML patients were enrolled in clinical trials. We, therefore, sought to conduct an evaluation (i) to determine population-based age-and gender-specific incidences of CML and other CMPDs (polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and myelomonocytic leukemia (CMML)) in a representative region of Germany, and (ii) to compare CML patients participating or not participating in clinical studies.
The study was carried out in a predefined area in Southwest Germany with 9.2 million inhabitants between January 1998 and December 2000. The area included the federal states of Baden-Wü rttemberg, Hessen, Rhineland-Palatinate and Saarland where demographics were similar. The borders to France, Luxembourg and Belgium in the South and West and geography (mountains) in the North and East limited patient fluctuation. All CMPD patients had the same access to medical treatment. If patients residing in the target area visited centers outside the reporting area, they were included in the study. Population data were obtained from the authorities. All 37 hematooncological centers including five university hospitals, 11 larger community hospitals and 21 specialty practices registered by the authorities were invited for cooperation. In addition, the 1792 hospitals and practices with focus internal medicine or pediatrics were contacted assuming that some of them also would treat CMPD cases. If a center had a newly diagnosed CML patient, resident in the study region, a completed standardized prospective questionnaire with pseudonymized data for sociodemographic and clinical baseline characteristics at the time of diagnosis was requested. For PV, ET, PMF, unclassified CMPD (UCMPD) and CMML, age, gender, area of residence and date of diagnosis were recorded. The definitions of diagnoses followed the World health organization criteria. BCR-ABL analysis by multiplex PCR was offered to confirm diagnosis of CML and to differentiate between CML and BCR-ABL-negative CMPD in atypical cases. As a reminder, the participating centers received follow-up letters and phone calls by the study center every 3 months.
All large hematooncological centers of the area (n ¼ 16) participated and reported 408 (46.5%) CMPD cases. Twelve of twenty-one hematooncological specialty practices (57.1%) reported 139 (15.8%) additional patients. The remaining patients were mostly recruited by practising internists (n ¼ 225, 25.7%) and smaller hospitals (n ¼ 99, 11.3%). Six cases (0.7%) were reported from 20 pediatric hospitals. The 877 reported CMPD cases (median age at the time of diagnosis, 67.9 years; range, 6.1-95. . Nine patients were younger than 20 years at diagnosis. A total of 460 (52.5%) of the 877 CMPD cases were men. The male-to-female ratio for CML, PV, PMF and CMML was 1.66, 1.10, 1.52 and 2.14, respectively, for ET 0.70. The overall crude annual incidence of CMPD cases was 3.18 per 100 000 per year ( Table 1 ). The age-specific incidence for all CMPD cases o65 years was 1.81 per 100 000 per year, for X65 years, it was 10.23, 1.95 and 13.14 for men and 1.65 and 8.37 for women, respectively ( Figure 1 ). Incidences for CMPD patients living in urban and rural areas were similar (3.28 and 3.14). A total of 218 cases were registered as CML: 172 (78.9%) patients had Ph/BCR-ABL-positive CML (median age, 56.8 years; range, 11.6-87.9), 18 (8.3%) patients had Ph/BCR-ABL-negative CML and for 28 (12.8%) patients cytogenetic/molecular status was unknown. The crude incidence of all 218 CML cases was 0.79, (0.62 for Ph/BCR-ABL-positive cases; Table 1 ). The crude age-specific incidence for all CML cases o65 years was 0.57, for X65 years it was 1.91, 0.73 and 2.90 for men and 0.42 and 1.27 for women, respectively.
In all, 110 (64%) of the 172 Ph/BCR-ABL-positive CML patients participated in clinical trials. Significantly different and independent features were age, prognostic score at diagnosis and management in a hospital. Patients participating (median age, 54.1 years) were on average 10.7 years younger than those who did not participate (median age, 64.8 years; P ¼ 0.0001; Figure 2 ). The chance for a Ph/BCR-ABL-positive CML patient o65 years to be enrolled in a clinical study was 3.8 times higher than for a CML patient X65 years (odds ratio (OR) ¼ 3.8, confidence interval (CI): 1.9-7.3). A low prognostic score (OR ¼ 2.3, CI: 1.1-4.8) and management in a hospital (OR ¼ 6.1, CI: 3.0-12.3) made inclusion in a study more likely. Male patients had a slightly higher probability to be enrolled in a study than females (OR ¼ 1.5, CI: 0.8-2.8). The living area (urban or rural) did not influence participation in clinical studies.
This epidemiological analysis is the first in Germany and the second in Europe that evaluates age-and gender-specific incidences of Ph/BCR-ABL-positive CML and compares sociodemographic and clinical characteristics of CML patients participating or not participating in clinical studies. The most interesting observation is the significant age difference between Ph/BCR-ABL-positive CML patients treated within or outside a clinical study, supporting the notion that elderly patients are underrepresented in clinical trials. This agrees with the age difference between published clinical trials and populationbased registries. Reasons for the noninclusion of elderly patients in trials might be comorbidities and a poorer prognostic score. Greater efforts to distinctly include elderly patients in clinical trials would provide a clear benefit also in the elderly with CML. The ELN (European LeukemiaNet; http://www.leukemia-net.org) therefore promotes Europe-wide leukemia (population-based) registries. A public (ELN)/private (Novartis Pharma, Novartis Table 1 Overall number of CMPD cases and crude annual incidence (1998-2000)
Number of newly diagnosed cases Crude incidence per 100 000 
Letters to the Editor
Oncology Region Europe, Origgio, Italy) partnership, the European Treatment and Outcome Study (http://www.eutos.org) on CML, has been started to accelerate the collection of CML data across Europe.
Our patients, participation rate in clinical trials of 64% is higher than that reported by the Scotland Leukemia Registry (52%). 6 An explanation might be the location of our study center inside the study area. The hematological baseline features of our CML patients including risk profile, cytogenetics and molecular genetics are comparable to those from randomized multicenter trials. Relatively more male CML patients are included in clinical trials than female patinets, corresponding to the observation that men accept experimental therapies more readily than women. 7 Some possible limitations of this epidemiological survey have to be addressed. Although all university and large community hospitals with focus hematooncology have reported cases, 9 of 21 (42.9%) specialty practices have not reported any case. This might indicate underreporting. Comparing the incidence of CML in this study, however, with that of the registry in Sweden, 4 where the referral structure is comparable but reporting is compulsory, incidences are similar arguing against serious underreporting of our study. A strong point of this study is the availability of the Ph/BCR-ABL status for the evaluation of CML incidences and of the median age at the time of diagnosis. 3 data with and without BCR-ABL status are not separately available, although both registries coded by the third edition of ICD-O. Consequently, the comparable crude rates of the Swedish Registry 4 and of the Cancer Registry of Saarland 3 report higher incidences (0.99 and 1.85) than our study as both registries included Ph/BCR-ABL-negative cases. Our CML incidence of Ph-positive CML (0.62) is similar to that reported by the Scotland Leukemia Registry 6 (0.64). As the Ph/BCR-ABL status was available for only 87.2% of our CML patients and not for any of the 61 patients with a diagnosis of CMML, incidence estimates provided here represent the lower margin of the true CML incidence. Of special interest are the variations of incidences among published reports of population-based registries [3] [4] [5] and surveys 2, 6 and between some of these reports and our study, as they might indicate geographic or ethnic variability beyond technical artifacts. Some registries try to increase data quality by standardization according to the age structure of the world standard population. The world standard population weighs age-specific incidences in populations with higher proportions of younger ages than in the European standard population. As all publications considered here stem from Northern Europe [2] [3] [4] 6 or from the United States, 5 and as CML and CMPD are primarily the diseases of the elderly, an age-specific evaluation appears more appropriate. There seems to be variability of incidences of geographic areas even in the same country as exemplified by the Swedish National Cancer Registry 4 and the Göteborg Central Disease Registry, 8 which report the incidences of PV and PMF that differ by a factor up to more than two. This is of interest, as differences in risk group composition between Southern (Italy) and Northern European countries (Germany and the United Kingdom) 9 have been reported. More population-based data with known BCR-ABL status are necessary to determine geographic or ethnic variations of BCR-ABL-positive CML.
On the basis of this survey, we conclude that reports of clinical studies underestimate the true age of the CML population and that elderly patients and women might have a lower chance to be included in trials. Geographic and/or ethnic variations might contribute to the variability of incidences among registries.
